In partnership with Alzheimer’s Research UK, Alzheimer’s Research and Therapy Editors-in-Chief, Dr. Douglas Galasko and Dr. Philip Scheltens, would like to invite you to our “Ask the Editor” virtual event.
Find out more here.
"Ask the Editors" with Alzheimer’s Research UK and Alzheimer’s Research and Therapy
Announcing the launch of Mini Reviews
Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here.
New Thematic Series - AI in Dementia
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here.
Articles
-
-
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
-
β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer’s disease
-
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
-
Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Alzheimer's blogs from BMC
Failed to load RSS feed.
Affiliated with
Annual Journal Metrics
-
Citation Impact
8.823 - 2-year Impact Factor (2021)
9.037 - 5-year Impact Factor (2021)
1.657 - Source Normalized Impact per Paper (SNIP)
2.802 - SCImago Journal Rank (SJR)Speed
26 days to first decision for all manuscripts (Median)
43 days to first decision for reviewed manuscripts only (Median)Usage
1,249,151 downloads (2021)
4,652 Altmetric mentions (2021)